Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2012
09/13/2012US20120231053 Block Copolymer For Intraperitoneal Administration Containing Anti-Cancer Agent, Micelle Preparation Thereof, And Cancer Therapeutic Agent Comprising The Micelle Preparation As Active Ingredient
09/13/2012US20120231052 Neuroprotection and myelin repair using nestorone®
09/13/2012US20120231051 Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
09/13/2012US20120231050 Synthetic Lactone Formulations and Method of Use
09/13/2012US20120231049 Freeze-Thaw Method For Modifying Stent Coating
09/13/2012US20120231047 Therapeutic agent delivery for the treatment of asthma via implantable and insertable medical devices
09/13/2012US20120231046 Implant for subcutaneous or intradermal injection
09/13/2012US20120231045 Sustained release compositions of alfuzosin
09/13/2012US20120231044 Vaccine formulation of mannose coated peptide particles
09/13/2012US20120231043 Immobilised biological entities
09/13/2012US20120231039 Chimeric immunomodulatory compounds and methods of using the same-iv
09/13/2012US20120231038 Wound Healing Compositions Comprising Biocompatible Cellulose Hydrogel Membranes and Methods of Use Thereof
09/13/2012US20120231037 Crystalline drug-containing coatings
09/13/2012US20120231020 Markers for selecting personalized therapies for the treatment of cancer
09/13/2012US20120231018 Heterocyclic aspartyl protease inhibitors
09/13/2012US20120231017 Heterocyclic aspartyl protease inhibitors
09/13/2012US20120231015 Fragile x mental retardation protein (fmrp), compositions, and methods related thereto
09/13/2012US20120231010 Vinpocetine and eburn amonine derivatives for promoting bone growth
09/13/2012US20120231008 Anti-C5A Binding Moieties with High Blocking Activity
09/13/2012US20120231007 Modulators of cell cycle progression
09/13/2012US20120231003 Ox2 Receptor Homologs
09/13/2012US20120231002 Treatment of vasculoproliferative conditions
09/13/2012US20120230995 Polyspecific binding molecules and uses thereof
09/13/2012US20120230992 Vegf-related protein
09/13/2012US20120230989 Methods and materials for treating renal cell carcinoma
09/13/2012US20120230986 Agent and Methods for Reducing Inflammatory Markers
09/13/2012US20120230984 Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds
09/13/2012US20120230983 Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
09/13/2012US20120230979 NOGO Receptor Binding Protein
09/13/2012US20120230978 Compositions and methods for modulating circadian synchronization
09/13/2012US20120230972 Salinosporamides and Methods for Use Thereof
09/13/2012US20120230971 Chromosomal modification involving the induction of double-stranded dna cleavage and homologous recombination at the cleavage site
09/13/2012US20120230964 The isolation and characterisation of heparan sulphates and their use in pharmaceutical compositions, methods of treatment and stem cell culture media suitable for conditions associated with bone repair
09/13/2012US20120230958 Oncolytic vaccinia virus combination cancer therapy
09/13/2012US20120230951 Antiviral compounds
09/13/2012US20120230943 Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
09/13/2012US20120230942 GEP, a novel chondrogenic growth factor and target in cartilage disorders
09/13/2012US20120230940 Conditioned cell culture medium compositions and methods of use
09/13/2012US20120230938 Polyconjugates for In Vivo Delivery of Polynucleotides
09/13/2012US20120230928 Compositions of active ingredients
09/13/2012US20120230916 Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof
09/13/2012DE102011013524A1 Gastroprotective agent comprises Exportal, which is 4-O-(beta-galactopyranosyl)-D-glucitomonohydrate)
09/13/2012DE102011005232A1 Adenosin und seine Derivate zur Verwendung in der Schmerztherapie Adenosine and its derivatives for use in the treatment of pain
09/13/2012CA2834990A1 Treatment of disorders with altered vascular barrier function
09/13/2012CA2832377A1 New pyridazinone and pyridone compounds
09/13/2012CA2830706A1 Quinolinone derivatives
09/13/2012CA2829801A1 Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid
09/13/2012CA2829583A1 Antibacterial or preserving composition containing 3-butoxy-1,2-propanediol
09/13/2012CA2829558A1 Pi3 kinase inhibitors and uses thereof
09/13/2012CA2829361A1 Peptide deformylase inhibitors
09/13/2012CA2829322A1 Androgen receptor antagonists and uses thereof
09/13/2012CA2829287A1 Pyrido [2,3-b] pyrazine derivatives and their therapeutical uses
09/13/2012CA2829259A1 Use of vanadium compounds for maintaining normaglycemia in a mammal
09/13/2012CA2829217A1 Compounds and methods of use in ablative radiotherapy
09/13/2012CA2829204A1 Oxaspiro[2.5]octane derivatives and analogs
09/13/2012CA2829200A1 Methods and compositions for treating depression using cyclobenzaprine
09/13/2012CA2829188A1 Dispiropyrrolidine derivatives
09/13/2012CA2829187A1 Dipyridylamine derivative
09/13/2012CA2829186A1 Amorphous form of lopinavir and ritonavir mixture
09/13/2012CA2829159A1 Nutraceutical composition for limiting the absorption of dietary lipids and for inducing weight loss, comprising, as active agent, at least one extract of carrot
09/13/2012CA2829131A1 Amino-quinolines as kinase inhibitors
09/13/2012CA2829126A1 Synthetic lta mimetics and use thereof as vaccine component for therapy and/or pro-phylaxis against gram-positive infections
09/13/2012CA2829118A1 Wound healant system and methods of use
09/13/2012CA2829086A1 Heavy-duty vehicle brake assembly with sealing interface
09/13/2012CA2829082A1 Heterocyclic modulators of lipid synthesis
09/13/2012CA2829026A1 (-)-huperzine a processes and related compositions and methods of treatment
09/13/2012CA2829015A1 Formulation comprising phenylaminopyrimidine derivative as active agent
09/13/2012CA2829010A1 Molecular targets for healing or treating wounds
09/13/2012CA2828999A1 Primary amine diazeniumdiolate heterocyclic derivatives
09/13/2012CA2828940A1 Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
09/13/2012CA2828909A1 Oleyl phosphocholine for the treatment of mycosis
09/13/2012CA2828896A1 Use of aptamers in therapy and/or diagnosis of autoimmune diseases
09/13/2012CA2828895A1 Substituted n-aryl pyridinones
09/13/2012CA2828772A1 Mutator activity induced by microrna-155 (mir-155) links inflammation and cancer
09/13/2012CA2828713A1 Alkyne substituted quinazoline compounds and methods of use
09/13/2012CA2828640A1 Use of glycopyrrolate for treating tachycardia
09/13/2012CA2828637A1 Semisolid aqueous pharmaceutical composition containing tapentadol
09/13/2012CA2828635A1 Parenteral administration of tapentadol
09/13/2012CA2828631A1 Aqueous pharmaceutical formulation of tapentadol for oral administration
09/13/2012CA2828610A1 Solid dispersion formulations and methods of use thereof
09/13/2012CA2828578A1 Mst1 kinase inhibitors and methods of their use
09/13/2012CA2828516A1 Method for producing 2-o-.alpha.-d-glucosyl-l-ascorbic acid anhydrous crystal-containing powder
09/13/2012CA2828415A1 Substituted morpholines as modulators for the calcium sensing receptor
09/13/2012CA2828395A1 Thiol-containing compounds for the removal of elements from tissues and formulations therefor
09/13/2012CA2828337A1 Fluoro-pyridinone derivatives useful as antibacterial agents
09/13/2012CA2826674A1 Tfeb phosphorylation inhibitors and uses thereof
09/13/2012CA2826640A1 Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
09/13/2012CA2825620A1 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (bace)
09/13/2012CA2825077A1 1,4 thiazepines/sulfones as bace1 and/or bace2 inhibitors
09/13/2012CA2813985A1 Melt-extruded solid dispersions containing an apoptosis-inducing agent
09/12/2012EP2497829A1 Super-agonistic anti-CD-28 antibodies
09/12/2012EP2497828A1 Use of aptamers in therapy and/or diagnosis of autoimmune diseases
09/12/2012EP2497827A1 Micro-RNAs that regulate muscle cell proliferation and differentiation
09/12/2012EP2497785A2 Hyaluronic acid derivative and drug containing the same
09/12/2012EP2497775A1 Ferrocene-based compounds and their use as ROS regulating prodrugs
09/12/2012EP2497774A1 Dihydro-oxazolobenzodiazepinone derivatives, processes for their preparation and pharmaceutical compositions comprising these compounds
09/12/2012EP2497772A1 Compound for inhibiting mitotic progression
09/12/2012EP2497771A1 4 -substituted azaadamantane derivatives and methods of use thereof
09/12/2012EP2497770A1 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
09/12/2012EP2497768A2 Novel 2, 4-pyrimidine derivatives and use thereof
1 ... 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 ... 7860